Recordati has received an unsolicited takeover offer from private equity group CVC Capital Partners that, if completed, would ...

AZ has yet to file for approval of Imfinzi in the frontline setting for earlier-stage HCC, despite its well-established role ...

Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, ...

His teams are trained to read where it will be three passes from now. In Formula 1, race strategy is no longer a gut call at ...

Trump started the Section 232 probe into pharma in the spring of 2025, using it as a lever for trade negotiations and MFN ...

The Roivant group company said that treatment with batoclimab had shown some improvement in the eye bulging (proptosis) ...

The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...

Top-line results from the OBERON and TITANIA trials showed that tozorakimab reduced the annualised rate of moderate-to-severe ...

A high burden of infectious diseases coexists with a rapid rise in non-communicable diseases such as diabetes, cancer, and ...

The FDA has ramped up the pressure on Amgen to withdraw Tavneos for a rare vasculitis condition from the market, with a ...

Three behavioural phenomena are particularly consequential in screening and prevention research: ...

In a new episode of the pharmaphorum podcast, recorded at BIO-Europe Spring in Lisbon, Portugal, web editor Nicole Raleigh ...